Today’s Stock Alert: What’s Immune Design Corp Downside After Making 52-Week Low?

Today's Stock Alert: What's Immune Design Corp Downside After Making 52 Week Low?

The stock of Immune Design Corp (NASDAQ:IMDZ) hit a new 52-week low and has $5.34 target or 11.00% below today’s $6.00 share price. The 9 months bearish chart indicates high risk for the $149.81M company. The 1-year low was reported on Oct, 28 by Barchart.com. If the $5.34 price target is reached, the company will be worth $16.48M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 18,594 shares traded hands. Immune Design Corp (NASDAQ:IMDZ) has declined 46.40% since March 28, 2016 and is downtrending. It has underperformed by 51.11% the S&P500.

Analysts await Immune Design Corp (NASDAQ:IMDZ) to report earnings on November, 10. They expect $-0.68 EPS, down 83.78% or $0.31 from last year’s $-0.37 per share. After $-0.71 actual EPS reported by Immune Design Corp for the previous quarter, Wall Street now forecasts -4.23% EPS growth.

Immune Design Corp (NASDAQ:IMDZ) Ratings Coverage

Out of 2 analysts covering Immune Design (NASDAQ:IMDZ), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Immune Design has been the topic of 4 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, August 10 by Jefferies. The stock has “Outperform” rating given by Leerink Swann on Tuesday, August 18. The firm has “Buy” rating by Jefferies given on Wednesday, September 9.

According to Zacks Investment Research, “Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.”

Insitutional Activity: The institutional sentiment increased to 1.25 in 2016 Q2. Its up 0.21, from 1.04 in 2016Q1. The ratio improved, as 8 funds sold all Immune Design Corp shares owned while 16 reduced positions. 8 funds bought stakes while 22 increased positions. They now own 9.57 million shares or 12.34% less from 10.92 million shares in 2016Q1.
The Pennsylvania-based Nationwide Fund Advisors has invested 0% in Immune Design Corp (NASDAQ:IMDZ). Blackrock Advisors Llc last reported 60,355 shares in the company. Blackrock reported 3,163 shares or 0% of all its holdings. Bnp Paribas Arbitrage Sa accumulated 436 shares or 0% of the stock. Wells Fargo & Com Mn has 0% invested in the company for 4,208 shares. The Pennsylvania-based Tfs Cap has invested 0.15% in Immune Design Corp (NASDAQ:IMDZ). National Bank Of America Corp De holds 1,422 shares or 0% of its portfolio. Blackrock Grp has 2,713 shares for 0% of their US portfolio. Walleye Trading Llc holds 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 200 shares. Spark Inv Lc has 0.06% invested in the company for 77,500 shares. Moreover, Point72 Asset Management L P has 0% invested in Immune Design Corp (NASDAQ:IMDZ) for 70,572 shares. Citigroup Inc reported 215 shares or 0% of all its holdings. Highbridge Cap Mgmt Ltd accumulated 0% or 26,452 shares. Abingworth Ltd Liability Partnership accumulated 197,300 shares or 1.69% of the stock. Jpmorgan Chase Co holds 0% of its portfolio in Immune Design Corp (NASDAQ:IMDZ) for 246,675 shares.

Insider Transactions: Since July 15, 2016, the stock had 4 buys, and 0 selling transactions for $10.26 million net activity. COLEMAN LEWIS W had bought 40,000 shares worth $250,000 on Tuesday, September 20. Another trade for 800,000 shares valued at $5.00 million was bought by Svennilson Peter. The insider Brady Stephen R bought $10,255. On Tuesday, September 20 COLUMN GROUP L P bought $5.00 million worth of the stock or 800,000 shares.

More notable recent Immune Design Corp (NASDAQ:IMDZ) news were published by: Quotes.Wsj.com which released: “News Immune Design Corp.IMDZ” on July 23, 2014, also Gurufocus.com with their article: “Immune Design Insider Buys Shares” published on October 03, 2016, Globenewswire.com published: “Immune Design and Gritstone Oncology Announce Clinical Collaboration for …” on May 09, 2016. More interesting news about Immune Design Corp (NASDAQ:IMDZ) were released by: Globenewswire.com and their article: “Immune Design Announces Presentations at the 2016 American Society of Clinical …” published on April 21, 2016 as well as Bizjournals.com‘s news article titled: “Immune Design posts $7.4 million Q3 loss” with publication date: November 12, 2015.

IMDZ Company Profile

Immune Design Corp., incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Firm focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Firm is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment